In bioanalysis of tissue specimens, there are two main options for long-term sample storage: formalin-fixed paraffin-embedded (FFPE) samples and frozen samples. An editorial article by Caitlin Smith, (found here) nicely outlines the benefits and detriments of each. Though FFPE samples are preferred for immunostaining and morphology, she concludes that frozen samples are preferable to FFPE samples for molecular analysis and native morphology for several reasons. Foremost among them is the higher potential for quality degradation during preparation and storage. Frozen specimens, which do not suffer the same degradation, are particularly necessary for analyses involving mass spectrometry, quantatative real-time PCR, and Western blotting.
CryoXtract Instruments, LLC will be offering a podium presentation and exhibiting at the Society for Laboratory Automation and Screening (SLAS) annual conference from January 24th-27th in San Diego. CryoXtract is also pleased to announce that their abstract was one of only 9 finalists selected for the SLAS Innovation Award. The $10,000 award is bestowed upon the podium presentation that is "exceedingly innovative and contributes to the exploration of technologies in the laboratory, exceeds a benchmark or milestone in screening or the lead discovery process, or demonstrates an advanced and integrated use of mature technologies."
On Wednesday, July 22 at 11am, CryoXtract will present a webinar entitled "Eliminating Freeze-thaw Cycles: Advances in Frozen Biospecimen Preservation and Utilization." This webinar is intended to provide the scientific community with information on new approaches for quick and effective frozen sample processing for experimental applications.
At this week’s SLAS conference held in Washington, D.C., CryoXtract offered “Ex vivo Stabilization of Small Molecule Compounds and Peptides in EDTA Plasma for LC-MS/MS Analysis Using Frozen Aliquotting,” an application note on its CXT 750 Frozen Sample Aliquotter and its potential for maintaining small molecule and peptide stability. This research, generated in collaboration with GlaxoSmithKline, demonstrates the benefits of the frozen aliquotting solution for applications in analytical chemistry and drug metabolism pharmacokinetics (DMPK) groups, and is a potentially significant development for improving drug stability in serum and plasma samples.
The research demonstrates the benefits of the frozen aliquotting solution as a valuable tool for compound stabilization and bioanalysis. In addition to improving clarity for bioanalysis by lessening the impact of ex vivo degradation and improving the efficiency of frozen sample utilization, frozen aliquotting could also potentially reduce the time required for assay development and validation and greatly simplify sample collection, processing, and handling protocols for bioanalytical efforts. These measures are required to keep the drug molecules sufficiently stable to permit meaningful analysis by mass spectrometry.
At last month’s annual conference of the European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB) in Leipzig, Germany, CryoXtract presented a poster on using frozen aliquotting for the preservation of analytical profiles in neurodegenerative research. The poster, entitled “Preserving Analytical Profiles of CNS Samples for Neurodegenerative Disease Research using Frozen Aliquotting Sample Handling Technology,” detailed potential improvements in sample processing techniques for central nervous system (CNS) disease tissue and biofluids biospecimens.
Freeze-thaw damage to highly sensitive CNS biospecimens can dramatically hinder the growing amount of research in the fields of neurodegenerative disease. By integrating frozen aliquotting into modern neurobiological research, greater access to high quality annotated CNS samples could yield improved diagnostic and treatment options for the growing populations facing diseases such as Alzheimer's and Parkinson's.
CryoXtract Instruments is excited to be presenting two posters and a display booth at the annual conference of the European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB) that starts tomorrow in Leipzig, Germany.
The biobanking industry needs to address growing information technology demands in order to be able to execute on best practices for research now and in the future, said Dee McGarvey, Director, CHTN Eastern Division, University of Pennsylvania, in an interview.
Biobank databases, for example, need to be comprehensive enough to hold large amounts of information and at the same time provide flexibility so that they can connect with a variety of complementary information systems. As the systems are designed and implemented, of primary concern is ensuring security since Patient Health Information (PHI) is involved.
“That’s probably one of the biggest issues that biobanks are working with right now,” McGarvey said. "How do you manage to keep the databases open so we can use them and access them and they can interact with all the other systems? How can we work within this framework and at the same time, maintain the security?”